Neuroleptic malignant syndrome (NMS)
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
Medication-Induced MovementG21.0
Loading…
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
≥3 of 12 catatonia symptoms: stupor; catalepsy; waxy flexibility; mutism; negativism; posturing; mannerism; stereotypy; agitation; grimacing; echolalia; echopraxia
Abnormal and prolonged contraction of muscles of eyes, face, neck, limbs, or trunk developing in association with medication use
Parkinsonian tremor, muscular rigidity, or akinesia developing in association with medication use (most commonly neuroleptic/antipsychotic or dopamine-depleting agent)
Medication-induced movement symptoms causing clinically significant distress or impairment
Intoxication: recent sedative/hypnotic/anxiolytic use; Withdrawal: cessation/reduction after prolonged heavy use
Involuntary movements (tardive dystonia: sustained/repetitive muscle contractions; tardive akathisia: subjective restlessness + repetitive movements) developing in association with neuroleptic use, persisting ≥4 weeks